Skip to main content

Institutional intelligence for Panjon Ltd

Cross-view mutual fund activity and super-investor shareholding · Jun 2026 SHP.

Tracked super investors holding ≥1%

Ownership breakdown

Estimated from named holders at or above 1% in the latest filing (Jun 2026). Official category totals not yet parsed. Sums to 85.57%.

  • Promoters56.63%
  • Retail & others (est.)28.94%
  • Super Investors 1.59%(subset)
  • 1% Club 12.84%(subset)

Super Investors and 1% Club names below are disclosed holders at or above 1%. They are subsets of the categories above, not additive.

Holder details (≥1% disclosed names)

1% Club — Individuals & others

Non-promoter ≥1% holders not matched to a curated profile

12.84%7 named
HolderStakeSharesValue (₹ Cr)
3.51%6,02,380₹1.1 Cr
2.55%4,37,500₹78.0 L
1.75%3,00,000₹54.0 L
1.40%2,39,513₹43.0 L
1.34%2,29,300₹41.0 L
1.26%2,15,716₹39.0 L
1.03%1,76,000₹32.0 L

Promoters

Promoter & promoter group

7 named
HolderStakeSharesValue (₹ Cr)
21.61%37,09,664₹6.7 Cr
11.71%20,10,000₹3.6 Cr
5.83%10,00,000₹1.8 Cr
5.83%10,00,000₹1.8 Cr
5.83%10,00,000₹1.8 Cr
2.91%5,00,200₹90.0 L
2.91%5,00,000₹90.0 L

Super Investors

Curated tracked investor profiles

1.59%1 named
HolderStakeSharesValue (₹ Cr)
Tracked as Mahendra Girdharilal1.59%2,73,596₹49.0 L

DII (other)

Insurance, banks, AIF, other domestic institutions

No names

No named holders ≥1% in this bucket.

FII / FPI

Foreign portfolio investors

No names

No named holders ≥1% in this bucket.

Mutual Funds

Domestic mutual funds & UTI

No names

No named holders ≥1% in this bucket.

Retail & others

Holders below 1% disclosure threshold and public non-institutions

SEBI requires naming only shareholders with ≥1% stake. The remaining includes retail investors, small HNIs, employee trusts, and other holders below the disclosure threshold — aggregated in the official filing.

Shareholding data sourced from NSE/BSE regulatory filings. Category chart uses official filing totals; named holder lists include every disclosed ≥1% position. Not investment advice. See our disclaimer and methodology.